RareMed Announces Expansion of Relationship with PTC Therapeutics
PTC(NASDAQ:PTC) PITTSBURGH, Sept. 2, 2025 /PRNewswire/ -- RareMed Solutions®, the nation's leader in patient support services for complex therapies, is proud to announce an expansion of its relationship with PTC Therapeutics™ with the launch of non-commercial pharmacy dispensing services for PTC's...
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
PTCOGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
PTC Appoints Jon Stevenson as Executive Vice President, Chief Product Officer
PTCBOSTON, Aug. 11, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that it has appointed Jon Stevenson as Executive Vice President, Chief Product Officer. Stevenson will be responsible for the strategy, development, and delivery of PTC's Digital Thread product portfolio. Stevenson...
Forecasting The Future: 11 Analyst Projections For PTC
PTCOppenheimer Maintains Outperform on PTC, Raises Price Target to $190
PTCOppenheimer Maintains Outperform on PTC, Raises Price Target to $190
PTC$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
PTCIf You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
PTCP/E Ratio Insights for PTC
PTCStifel Maintains Buy on PTC, Lowers Price Target to $200
PTCBaird Maintains Outperform on PTC, Raises Price Target to $191
PTCRosenblatt Maintains Buy on PTC, Maintains $204 Price Target
PTCPiper Sandler Maintains Neutral on PTC, Lowers Price Target to $180
PTCPTC Raises FY2025 Adj EPS Guidance from $5.30-$6.00 to $5.80-$6.55 vs $5.68 Est; Raises FY2025 Sales Guidance from $2.43B-$2.53B to $2.44B-$2.56B vs $2.48B Est
PTCPTC Sees Q3 Adj EPS $1.05-$1.30 vs $1.37 Est; Sees Sales $560.000M-$600.000M vs $611.76M Est
PTCPTC Q2 Adj. EPS $1.79 Beats $1.40 Estimate, Sales $636.37M Beat $607.08M Estimate
PTCWhere PTC Stands With Analysts
PTCOppenheimer Maintains Outperform on PTC, Lowers Price Target to $170
PTCHere's How Much $100 Invested In PTC 10 Years Ago Would Be Worth Today
PTCBaird Maintains Outperform on PTC, Raises Price Target to $185
PTCKeybanc Maintains Overweight on PTC, Lowers Price Target to $185
PTCMizuho Maintains Neutral on PTC, Lowers Price Target to $160
PTCBarclays Maintains Overweight on PTC, Lowers Price Target to $175
PTCP/E Ratio Insights for PTC
PTCJP Morgan Downgrades PTC to Neutral, Lowers Price Target to $160
PTCHere's How Much $100 Invested In PTC 5 Years Ago Would Be Worth Today
PTCHow Do Investors Really Feel About PTC?
PTCPTC Announces Acquisition Of IncQuery Group
PTC$100 Invested In PTC 10 Years Ago Would Be Worth This Much Today
PTCIf You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
PTCIs the Market Bullish or Bearish on PTC?
PTCHere's How Much $100 Invested In PTC 10 Years Ago Would Be Worth Today
PTCP/E Ratio Insights for PTC
PTCPrice Over Earnings Overview: PTC
PTCPTC Sees FY 2024 Revenue $2.505B-$2.605B Vs $2.293B Est
PTCPTC Authorizes $2B Share Repurchase Through 2027, Plans $300M Buyback In Fiscal 2025 As Part Of Strategy To Return 50% Of Free Cash Flow To Shareholders
PTCPTC Q4 2024 Adj EPS $1.54 Beats $1.45 Estimate, Sales $626.55M Beat $620.53M Estimate
PTCAn Overview of PTC's Earnings
PTCHere's How Much You Would Have Made Owning PTC Stock In The Last 10 Years
PTCHow Is The Market Feeling About PTC?
PTCBarclays Maintains Overweight on PTC, Lowers Price Target to $120
PTCMizuho Maintains Buy on PTC, Raises Price Target to $135
PTC